Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK
Status:
Completed
Trial end date:
2021-05-16
Target enrollment:
Participant gender:
Summary
This study is to investigate the pharmacokinetic (PK) and safety of M2951 (Bruton's tyrosine
kinase [BTK] inhibitor) in participants with different degrees of hepatic impairment compared
to participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany